Bacteriophage therapy as an effective alternative to antibiotics

Bacteriophages, viruses that parasitize bacteria, were first discovered by Frederick Twort over a century ago in 1915. They were independently rediscovered by Felix d’Hérelle in 1917, and he coined the term, bacteriophage that translates into bacterial eater from the Greek. Shortly afterward, bacteriophages were used as therapeutic agents for bacterial infections during the 1920s and 30s. Phage research and therapy was actively pursued in the country of Georgia and other parts of east and central Europe well into the 1970s. However in most parts of the world, the discovery of safe and effective antibiotics replaced phage therapy. Bacteriophages are widely distributed around the planet and the estimate is that there are 10^31 phage particles – a number that is ten to one hundred times the number of bacteria. Phages are host specific and rely on the presence of attachment sites that are not only species but often strain specific. Thus when they are applied, they can eliminate the bacterium of interest without disturbing the rest of the microbial flora. Now that antibiotic resistance has become widespread and the number of new antibiotics has dwindled, it is critical to look at new strategies for the management of multi-drug resistant organisms. The list of alternatives includes vaccines, monoclonal antibodies and phages. While phages are not currently used for direct therapeutic benefit, they have been applied in Europe to eliminate the pathogen, Listeria, from cheese products. In the past, phages were directly administered to humans for the treatment of dysentery, Pseudomonas aeruginosa-mediated chronic otitis or pulmonary infection, vancomycin-resistant Enterococcus faecium sepsis, mixed infections caused by Staphylococcus aureus and Streptococcus pyogenes, E. coli O157:H7 enteric infection and infections in cystic fibrosis patients caused by Burkholderia cenocepacia. Any effort to restart the therapeutic usage of bacteriophages would require research funding and development of regulations parallel to those in place for antibiotics or other drugs licensed for use in humans.

Biography

Byungse Suh has completed his BS in Pharmacy in 1962 from Chung-Ang University, Korea; MS and PhD in Microbiology in 1967 and 1969, respectively from the University of Kansas; Postdoctoral studies in Biochemistry from University of Iowa; and MD from the University of Miami in 1973. He has completed Internal Medicine Residency Training (1973-1976) and an Infectious Disease Fellowship (1976-1978) at the University of Wisconsin School of Medicine and Public Health. He has published more than 110 papers and is a Professor at Temple University School of Medicine since 1978.

bingsuh@temple.edu